Transplant patients likely have a higher risk of COVID-19 complications

While there are still many mysteries about COVID-19, we do know that some populations—including older adults and those with underlying medical conditions—are more susceptible to severe infection than others. Even under the best circumstances, transplant patients face the possibility of a host of complications, and the current pandemic certainly increases their risk.

One reason for this is that transplant patients must be on immunosuppression drugs following any solid organ transplant.  These drugs are designed to increase the chances that the body will not reject the transplanted organ after an operation. However, immunosuppression diminishes the body’s immune system and its ability to respond to new infections.

Another reason transplant patients may be at increased risk for severe complications from COVID-19 is that those individuals typically have an underlying medical condition that led to end-stage organ failure, and those conditions are not always completely mitigated by the transplant. This suggests that transplant patients with prior underlying medical conditions or preexisting health problems are at an extreme disadvantage for successfully fighting off an infection and have a significantly higher risk for life-threatening complications from the coronavirus.

These risk factors make it even more crucial for transplant patients and their friends and loved ones to follow the COVID-19 guidelines recommended by the CDC. This includes continuing to practice social distancing, avoiding those you suspect of being ill, avoiding crowds, and not travelling unless it’s absolutely necessary. If you have questions or concerns regarding your health, contact your primary care physician, transplant coordinator or transplant physician.

Tags:

avatar

About Mark Slaughter, M.D.

Dr. Mark Slaughter is professor of Surgery and chair of the Department of Cardiovascular and Thoracic Surgery at the University of Louisville and has an adjunct appointment in the Department of Bioengineering. In addition, he serves as the director of the Heart Transplant and Mechanical Assist Device Program at the University of Louisville and Jewish Hospital. Dr. Slaughter currently serves as a consultant to the FDA Medical Device Review Panel, National Science Foundation SBIR/STTR grant reviewer and previously served two terms for the Health and Human Services Medicare Coverage Advisory Committee. Dr. Slaughter has served as the president of the American Society Artificial Internal Organs and president of the International Society of Rotary Blood Pumps. Dr. Slaughter is the editor-in-chief of the American Society of Artificial Internal Organs Journal and also serves as an associate editor for the Annals of Thoracic Surgery.

All posts by Mark Slaughter, M.D.